Osimertinib plus savolitinib in EGFRm+/MET+ NSCLC following prior osimertinib - SAVANNAH

Study identifier:D5084C00007

ClinicalTrials.gov identifier:NCT03778229

EudraCT identifier:2018-003012-51

CTIS identifier:2024-512564-58-00

Recruitment Complete

Official Title

A Phase II Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib.

Medical condition

Carcinoma

Phase

Phase 2

Healthy volunteers

No

Study drug

osimertinib, savolitinib, placebo

Sex

All

Actual Enrollment

366

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 09 Jan 2019
Estimated Primary Completion Date: 23 Aug 2024
Estimated Study Completion Date: 28 May 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Hutchison MediPharma

Inclusion and exclusion criteria